DIADIA0.72%
SPYSPY0.99%
QQQQQQ1.30%
Trending
Top trending tickerPLTRPLTR6.70%
SPYSPY0.99%
QQQQQQ1.30%
WAGMIWAGMI17.06%
SLAPSLAP0.84%
SRPTSRPT40.12%
HIMSHIMS0.50%
ICPICP31.09%
BMNRBMNR3.97%
ZECZEC22.03%
Top trending tickerPLTRPLTR6.70%
SPYSPY0.99%
QQQQQQ1.30%
WAGMIWAGMI17.06%
SLAPSLAP0.84%
SRPTSRPT40.12%
HIMSHIMS0.50%
ICPICP31.09%
BMNRBMNR3.97%
ZECZEC22.03%
homeSymbolHIMS
HIMS logo

HIMS
Hims & Hers Health Inc

47,930
Mkt Cap
$10.03B
Volume
346,820.00
52W High
$72.98
52W Low
$19.15
PE Ratio
55.56
HIMS Fundamentals
Price
$44.61
Prev Close
$45.46
Open
$46.90
50D MA
$51.41
Beta
2.03
Avg. Volume
28.29M
EPS (Annual)
$0.5322
P/B
17.81
Rev/Employee
$901,963.35
Loading...
Loading...

Feed

News

Sentiment

Earnings

Fundamentals

Info

News
all
press releases
Hims & Hers Health Stock Jumps After-Hours As Q3 Growth, Novo Nordisk Talks Fuel Bullish Retail Bets
Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.
Stocktwits·7h ago
News Placeholder
More News
News Placeholder
Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates
Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 0.00% and +2.62%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12h ago
News Placeholder
Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results
Hims & Hers Health, Inc. (Hims & Hers or the Company, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2025, in a...
Business Wire·14h ago
News Placeholder
Hims & Hers Q3 Preview: GLP-1 Drug Expansion Draws Investor Focus
The company is expected to post third-quarter revenue of $579.9 million and earnings per share of $0.10, according to data from Fiscal AI.
Stocktwits·18h ago
News Placeholder
OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Zacks·18h ago
News Placeholder
Hims & Hers Scales AI-Driven Personalized Health and Wellness
HIMS scales AI-driven care with new hormonal health lines, global expansion plans and a $870 million funding boost.
Zacks·4d ago
News Placeholder
LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc.
LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc. LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc...
PR Newswire·6d ago
News Placeholder
Can Sustained Product Demand Drive HIMS Stock Before Q3 Earnings?
Hims & Hers benefits from strong platform engagement and hormonal health launches ahead of third-quarter 2025 earnings.
Zacks·6d ago
News Placeholder
Analysts Estimate Nyxoah SA (NYXH) to Report a Decline in Earnings: What to Look Out for
Nyxoah (NYXH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·6d ago
News Placeholder
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
Hims & Hers Health, Inc. (HIMS) reached $47.12 at the closing of the latest trading day, reflecting a -2.3% change compared to its last close.
Zacks·7d ago

Latest HIMS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.